Regulus Therapeutics to Raise $42.8M in a Public Offering
By Catherine Shaffer
Wednesday, July 17, 2013
A new public offering of 4.5 million shares of common stock at $9.50 per share will help to float Regulus Therapeutics Inc.'s pipeline of drugs targeting microRNAs, including its lead compound RG-101 for hepatitis C virus.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.